USFDA completes inspection at Suven Life's Pashamylaram unit

07 May 2018 Evaluate

Suven Life Science has undergone US Food and Drug Administration (USFDA) renewal inspection at their facility in Pashamylaram near Hyderabad for the manufacture and supply of active pharmaceutical ingredients (bulk drugs), intermediates and formulations under cGMP during February 5 - 15, 2018.

Based on this USFDA inspection and the review thereafter, the facility is considered to be in an acceptable state of compliance with regards to Current Good Manufacturing Processes (CGMP) and the agency has determined that the inspection classification of this facility is No Action Indicated (NAI).

Also, USFDA has concluded that the inspection is closed and the agency has issued an Establishment Inspection Report (EIR) for its facility at Pashamylaram. So far, the company has filed 19 DMF’s and 5 ANDA’s from this facility which is USFDA complaint under cGMP and continued after renewal inspection.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets.


Suven Life Sciences Share Price

133.50 -3.40 (-2.48%)
23-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.65
Dr. Reddys Lab 1235.15
Cipla 1314.85
Zydus Lifesciences 881.95
Lupin 2137.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×